
Sign up to save your podcasts
Or


Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.
By The Motley Fool4.7
16041,604 ratings
Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.

3,217 Listeners

1,482 Listeners

808 Listeners

944 Listeners

521 Listeners

1,170 Listeners

2,201 Listeners

825 Listeners

1,422 Listeners

1,038 Listeners

9,715 Listeners

195 Listeners

833 Listeners

84 Listeners

584 Listeners

1,049 Listeners

56 Listeners